nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP2D6—Hydroxyurea—head and neck cancer	0.0932	0.252	CbGbCtD
Ziprasidone—CYP3A7—Docetaxel—head and neck cancer	0.0591	0.16	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0591	0.16	CbGbCtD
Ziprasidone—CYP3A5—Docetaxel—head and neck cancer	0.0443	0.12	CbGbCtD
Ziprasidone—CYP1A2—Fluorouracil—head and neck cancer	0.0432	0.117	CbGbCtD
Ziprasidone—CYP2D6—Vinblastine—head and neck cancer	0.033	0.0891	CbGbCtD
Ziprasidone—DRD5—eyelid—head and neck cancer	0.0233	0.127	CbGeAlD
Ziprasidone—CYP3A4—Vinblastine—head and neck cancer	0.021	0.0567	CbGbCtD
Ziprasidone—CYP3A4—Docetaxel—head and neck cancer	0.0173	0.0467	CbGbCtD
Ziprasidone—HTR7—superior cervical ganglion—head and neck cancer	0.0144	0.078	CbGeAlD
Ziprasidone—HTR1B—trigeminal nerve—head and neck cancer	0.0105	0.0572	CbGeAlD
Ziprasidone—HTR1D—trigeminal nerve—head and neck cancer	0.0102	0.0553	CbGeAlD
Ziprasidone—HTR3A—cranial nerve—head and neck cancer	0.00894	0.0486	CbGeAlD
Ziprasidone—HRH1—nose—head and neck cancer	0.00772	0.0419	CbGeAlD
Ziprasidone—HTR1B—cranial nerve—head and neck cancer	0.0075	0.0407	CbGeAlD
Ziprasidone—HTR1D—cranial nerve—head and neck cancer	0.00726	0.0394	CbGeAlD
Ziprasidone—HTR7—cranial nerve—head and neck cancer	0.00578	0.0314	CbGeAlD
Ziprasidone—HTR2A—trigeminal nerve—head and neck cancer	0.00506	0.0275	CbGeAlD
Ziprasidone—H1F0—hair follicle—head and neck cancer	0.00402	0.0218	CbGeAlD
Ziprasidone—HTR2A—cranial nerve—head and neck cancer	0.00361	0.0196	CbGeAlD
Ziprasidone—CHRM3—exocrine gland—head and neck cancer	0.00274	0.0149	CbGeAlD
Ziprasidone—H1F0—neck—head and neck cancer	0.0027	0.0147	CbGeAlD
Ziprasidone—Neoplasm—Vinblastine—head and neck cancer	0.00248	0.00842	CcSEcCtD
Ziprasidone—Blood urea increased—Hydroxyurea—head and neck cancer	0.00236	0.00802	CcSEcCtD
Ziprasidone—Phlebitis—Vinblastine—head and neck cancer	0.00231	0.00785	CcSEcCtD
Ziprasidone—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00227	0.00772	CcSEcCtD
Ziprasidone—Neoplasm—Hydroxyurea—head and neck cancer	0.00226	0.00768	CcSEcCtD
Ziprasidone—H1F0—parotid gland—head and neck cancer	0.0022	0.0119	CbGeAlD
Ziprasidone—CHRM5—epithelium—head and neck cancer	0.00213	0.0116	CbGeAlD
Ziprasidone—H1F0—saliva-secreting gland—head and neck cancer	0.0021	0.0114	CbGeAlD
Ziprasidone—Speech disorder—Fluorouracil—head and neck cancer	0.00209	0.00711	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Vinblastine—head and neck cancer	0.00203	0.0069	CcSEcCtD
Ziprasidone—Renal failure acute—Hydroxyurea—head and neck cancer	0.00196	0.00668	CcSEcCtD
Ziprasidone—HTR7—mouth—head and neck cancer	0.00195	0.0106	CbGeAlD
Ziprasidone—H1F0—connective tissue—head and neck cancer	0.00193	0.0105	CbGeAlD
Ziprasidone—HTR1E—head—head and neck cancer	0.00193	0.0105	CbGeAlD
Ziprasidone—Leukocytosis—Fluorouracil—head and neck cancer	0.00191	0.00651	CcSEcCtD
Ziprasidone—Liver disorder—Docetaxel—head and neck cancer	0.0019	0.00647	CcSEcCtD
Ziprasidone—Dysarthria—Fluorouracil—head and neck cancer	0.0019	0.00646	CcSEcCtD
Ziprasidone—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.0019	0.00645	CcSEcCtD
Ziprasidone—DRD5—lymphoid tissue—head and neck cancer	0.00183	0.00993	CbGeAlD
Ziprasidone—Throat sore—Docetaxel—head and neck cancer	0.0018	0.00612	CcSEcCtD
Ziprasidone—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.00178	0.00607	CcSEcCtD
Ziprasidone—Dermatitis contact—Fluorouracil—head and neck cancer	0.00178	0.00604	CcSEcCtD
Ziprasidone—Dermatitis atopic—Docetaxel—head and neck cancer	0.00175	0.00596	CcSEcCtD
Ziprasidone—Face oedema—Hydroxyurea—head and neck cancer	0.00175	0.00595	CcSEcCtD
Ziprasidone—Scotoma—Docetaxel—head and neck cancer	0.00171	0.00581	CcSEcCtD
Ziprasidone—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.0017	0.00578	CcSEcCtD
Ziprasidone—CHRM4—head—head and neck cancer	0.00169	0.00918	CbGeAlD
Ziprasidone—Photophobia—Fluorouracil—head and neck cancer	0.00169	0.00574	CcSEcCtD
Ziprasidone—Angina pectoris—Vinblastine—head and neck cancer	0.00167	0.00569	CcSEcCtD
Ziprasidone—HTR7—neck—head and neck cancer	0.00166	0.00904	CbGeAlD
Ziprasidone—Breast disorder—Hydroxyurea—head and neck cancer	0.00164	0.00557	CcSEcCtD
Ziprasidone—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00163	0.00556	CcSEcCtD
Ziprasidone—H1F0—trachea—head and neck cancer	0.00162	0.00882	CbGeAlD
Ziprasidone—CHRM1—parotid gland—head and neck cancer	0.00159	0.00865	CbGeAlD
Ziprasidone—DRD3—head—head and neck cancer	0.00157	0.00854	CbGeAlD
Ziprasidone—Sepsis—Fluorouracil—head and neck cancer	0.00156	0.00531	CcSEcCtD
Ziprasidone—CHRM1—saliva-secreting gland—head and neck cancer	0.00152	0.00828	CbGeAlD
Ziprasidone—HTR6—head—head and neck cancer	0.00151	0.00822	CbGeAlD
Ziprasidone—Thrombophlebitis—Fluorouracil—head and neck cancer	0.00151	0.00513	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Vinblastine—head and neck cancer	0.0015	0.00511	CcSEcCtD
Ziprasidone—HTR1D—connective tissue—head and neck cancer	0.0015	0.00814	CbGeAlD
Ziprasidone—Amenorrhoea—Docetaxel—head and neck cancer	0.00148	0.00502	CcSEcCtD
Ziprasidone—DRD5—head—head and neck cancer	0.00147	0.008	CbGeAlD
Ziprasidone—Dysuria—Hydroxyurea—head and neck cancer	0.00147	0.00498	CcSEcCtD
Ziprasidone—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00143	0.00485	CcSEcCtD
Ziprasidone—Weight increased—Hydroxyurea—head and neck cancer	0.00143	0.00485	CcSEcCtD
Ziprasidone—H1F0—lymphoid tissue—head and neck cancer	0.00141	0.00768	CbGeAlD
Ziprasidone—Oliguria—Docetaxel—head and neck cancer	0.00141	0.00479	CcSEcCtD
Ziprasidone—Drug interaction—Docetaxel—head and neck cancer	0.0014	0.00476	CcSEcCtD
Ziprasidone—Infestation NOS—Hydroxyurea—head and neck cancer	0.0014	0.00475	CcSEcCtD
Ziprasidone—Infestation—Hydroxyurea—head and neck cancer	0.0014	0.00475	CcSEcCtD
Ziprasidone—Amnesia—Fluorouracil—head and neck cancer	0.00139	0.00472	CcSEcCtD
Ziprasidone—Haemoglobin—Vinblastine—head and neck cancer	0.00138	0.0047	CcSEcCtD
Ziprasidone—Haemorrhage—Vinblastine—head and neck cancer	0.00138	0.00468	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00137	0.00466	CcSEcCtD
Ziprasidone—Hypoaesthesia—Vinblastine—head and neck cancer	0.00137	0.00465	CcSEcCtD
Ziprasidone—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00137	0.00464	CcSEcCtD
Ziprasidone—Pharyngitis—Vinblastine—head and neck cancer	0.00137	0.00464	CcSEcCtD
Ziprasidone—CHRM3—saliva-secreting gland—head and neck cancer	0.00136	0.00741	CbGeAlD
Ziprasidone—Lethargy—Fluorouracil—head and neck cancer	0.00133	0.00453	CcSEcCtD
Ziprasidone—CHRM5—head—head and neck cancer	0.00132	0.00718	CbGeAlD
Ziprasidone—Osteoarthritis—Fluorouracil—head and neck cancer	0.00131	0.00444	CcSEcCtD
Ziprasidone—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.0013	0.00441	CcSEcCtD
Ziprasidone—Pulmonary embolism—Docetaxel—head and neck cancer	0.0013	0.00441	CcSEcCtD
Ziprasidone—H1F0—thyroid gland—head and neck cancer	0.00128	0.00698	CbGeAlD
Ziprasidone—Haemoglobin—Hydroxyurea—head and neck cancer	0.00126	0.00429	CcSEcCtD
Ziprasidone—Haemorrhage—Hydroxyurea—head and neck cancer	0.00125	0.00427	CcSEcCtD
Ziprasidone—ADRA2C—parotid gland—head and neck cancer	0.00125	0.00677	CbGeAlD
Ziprasidone—Ataxia—Fluorouracil—head and neck cancer	0.00123	0.00417	CcSEcCtD
Ziprasidone—Neuropathy—Docetaxel—head and neck cancer	0.00122	0.00414	CcSEcCtD
Ziprasidone—Alopecia—Vinblastine—head and neck cancer	0.00122	0.00413	CcSEcCtD
Ziprasidone—ADRA1B—head—head and neck cancer	0.00121	0.00656	CbGeAlD
Ziprasidone—HTR7—connective tissue—head and neck cancer	0.00119	0.00648	CbGeAlD
Ziprasidone—CHRM1—trachea—head and neck cancer	0.00118	0.00639	CbGeAlD
Ziprasidone—Neoplasm—Docetaxel—head and neck cancer	0.00117	0.00399	CcSEcCtD
Ziprasidone—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00117	0.00397	CcSEcCtD
Ziprasidone—Lightheadedness—Docetaxel—head and neck cancer	0.00116	0.00395	CcSEcCtD
Ziprasidone—H1F0—head—head and neck cancer	0.00114	0.00619	CbGeAlD
Ziprasidone—Angiopathy—Hydroxyurea—head and neck cancer	0.00114	0.00387	CcSEcCtD
Ziprasidone—HTR7—epithelium—head and neck cancer	0.00113	0.00615	CbGeAlD
Ziprasidone—Dysphagia—Fluorouracil—head and neck cancer	0.00113	0.00384	CcSEcCtD
Ziprasidone—Sepsis—Docetaxel—head and neck cancer	0.00113	0.00383	CcSEcCtD
Ziprasidone—Chills—Hydroxyurea—head and neck cancer	0.00113	0.00383	CcSEcCtD
Ziprasidone—DRD1—head—head and neck cancer	0.00112	0.00611	CbGeAlD
Ziprasidone—Eosinophilia—Fluorouracil—head and neck cancer	0.00112	0.0038	CcSEcCtD
Ziprasidone—Alopecia—Hydroxyurea—head and neck cancer	0.00111	0.00377	CcSEcCtD
Ziprasidone—Anaemia—Vinblastine—head and neck cancer	0.00111	0.00376	CcSEcCtD
Ziprasidone—Angina pectoris—Fluorouracil—head and neck cancer	0.0011	0.00374	CcSEcCtD
Ziprasidone—Phlebitis—Docetaxel—head and neck cancer	0.00109	0.00372	CcSEcCtD
Ziprasidone—ADRA1A—epithelium—head and neck cancer	0.00109	0.00594	CbGeAlD
Ziprasidone—Erythema—Hydroxyurea—head and neck cancer	0.00109	0.00371	CcSEcCtD
Ziprasidone—Thrombophlebitis—Docetaxel—head and neck cancer	0.00109	0.0037	CcSEcCtD
Ziprasidone—HTR3A—head—head and neck cancer	0.00109	0.0059	CbGeAlD
Ziprasidone—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00108	0.00368	CcSEcCtD
Ziprasidone—Vertigo—Vinblastine—head and neck cancer	0.00108	0.00366	CcSEcCtD
Ziprasidone—Leukopenia—Vinblastine—head and neck cancer	0.00107	0.00364	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00105	0.00356	CcSEcCtD
Ziprasidone—HTR2A—neck—head and neck cancer	0.00104	0.00564	CbGeAlD
Ziprasidone—Hypertension—Vinblastine—head and neck cancer	0.00103	0.00352	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00103	0.0035	CcSEcCtD
Ziprasidone—Pneumonia—Fluorouracil—head and neck cancer	0.00101	0.00344	CcSEcCtD
Ziprasidone—Anaemia—Hydroxyurea—head and neck cancer	0.00101	0.00343	CcSEcCtD
Ziprasidone—Infestation NOS—Fluorouracil—head and neck cancer	0.00101	0.00342	CcSEcCtD
Ziprasidone—Infestation—Fluorouracil—head and neck cancer	0.00101	0.00342	CcSEcCtD
Ziprasidone—HTR7—trachea—head and neck cancer	0.001	0.00544	CbGeAlD
Ziprasidone—Atrial fibrillation—Docetaxel—head and neck cancer	0.000994	0.00338	CcSEcCtD
Ziprasidone—Visual disturbance—Docetaxel—head and neck cancer	0.000994	0.00338	CcSEcCtD
Ziprasidone—Renal impairment—Docetaxel—head and neck cancer	0.00099	0.00337	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000986	0.00335	CcSEcCtD
Ziprasidone—Dermatitis bullous—Docetaxel—head and neck cancer	0.000986	0.00335	CcSEcCtD
Ziprasidone—Conjunctivitis—Fluorouracil—head and neck cancer	0.000978	0.00332	CcSEcCtD
Ziprasidone—Leukopenia—Hydroxyurea—head and neck cancer	0.000978	0.00332	CcSEcCtD
Ziprasidone—Lethargy—Docetaxel—head and neck cancer	0.000962	0.00327	CcSEcCtD
Ziprasidone—Thrombocytopenia—Vinblastine—head and neck cancer	0.000957	0.00325	CcSEcCtD
Ziprasidone—Epistaxis—Fluorouracil—head and neck cancer	0.000949	0.00323	CcSEcCtD
Ziprasidone—Hyponatraemia—Docetaxel—head and neck cancer	0.000946	0.00322	CcSEcCtD
Ziprasidone—Pain in extremity—Docetaxel—head and neck cancer	0.000942	0.0032	CcSEcCtD
Ziprasidone—Anorexia—Vinblastine—head and neck cancer	0.000932	0.00317	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000924	0.00314	CcSEcCtD
Ziprasidone—ADRA2C—trachea—head and neck cancer	0.000921	0.005	CbGeAlD
Ziprasidone—HTR1B—head—head and neck cancer	0.000912	0.00495	CbGeAlD
Ziprasidone—Haemoglobin—Fluorouracil—head and neck cancer	0.000908	0.00309	CcSEcCtD
Ziprasidone—CHRM2—head—head and neck cancer	0.000907	0.00493	CbGeAlD
Ziprasidone—Rhinitis—Fluorouracil—head and neck cancer	0.000905	0.00308	CcSEcCtD
Ziprasidone—Haemorrhage—Fluorouracil—head and neck cancer	0.000903	0.00307	CcSEcCtD
Ziprasidone—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000899	0.00305	CcSEcCtD
Ziprasidone—Pharyngitis—Fluorouracil—head and neck cancer	0.000896	0.00305	CcSEcCtD
Ziprasidone—HRH1—connective tissue—head and neck cancer	0.000891	0.00484	CbGeAlD
Ziprasidone—Ataxia—Docetaxel—head and neck cancer	0.000886	0.00301	CcSEcCtD
Ziprasidone—Infection—Hydroxyurea—head and neck cancer	0.000886	0.00301	CcSEcCtD
Ziprasidone—HTR1D—head—head and neck cancer	0.000882	0.00479	CbGeAlD
Ziprasidone—Paraesthesia—Vinblastine—head and neck cancer	0.000878	0.00298	CcSEcCtD
Ziprasidone—Dehydration—Docetaxel—head and neck cancer	0.000876	0.00298	CcSEcCtD
Ziprasidone—ADRA2A—connective tissue—head and neck cancer	0.000875	0.00475	CbGeAlD
Ziprasidone—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000874	0.00297	CcSEcCtD
Ziprasidone—HTR2C—head—head and neck cancer	0.000874	0.00475	CbGeAlD
Ziprasidone—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000873	0.00297	CcSEcCtD
Ziprasidone—Liver function test abnormal—Docetaxel—head and neck cancer	0.00087	0.00296	CcSEcCtD
Ziprasidone—Skin disorder—Hydroxyurea—head and neck cancer	0.000866	0.00294	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000861	0.00293	CcSEcCtD
Ziprasidone—Breast disorder—Docetaxel—head and neck cancer	0.000852	0.00289	CcSEcCtD
Ziprasidone—Anorexia—Hydroxyurea—head and neck cancer	0.00085	0.00289	CcSEcCtD
Ziprasidone—Decreased appetite—Vinblastine—head and neck cancer	0.00085	0.00289	CcSEcCtD
Ziprasidone—Cramp muscle—Docetaxel—head and neck cancer	0.000849	0.00288	CcSEcCtD
Ziprasidone—HRH1—epithelium—head and neck cancer	0.000846	0.00459	CbGeAlD
Ziprasidone—Nasopharyngitis—Docetaxel—head and neck cancer	0.000843	0.00286	CcSEcCtD
Ziprasidone—ADRA1A—lymphoid tissue—head and neck cancer	0.000841	0.00457	CbGeAlD
Ziprasidone—Constipation—Vinblastine—head and neck cancer	0.000836	0.00284	CcSEcCtD
Ziprasidone—CHRM3—thyroid gland—head and neck cancer	0.000832	0.00452	CbGeAlD
Ziprasidone—SLC6A4—head—head and neck cancer	0.000828	0.0045	CbGeAlD
Ziprasidone—CHRM1—head—head and neck cancer	0.000825	0.00448	CbGeAlD
Ziprasidone—Dysphagia—Docetaxel—head and neck cancer	0.000814	0.00277	CcSEcCtD
Ziprasidone—Arrhythmia—Fluorouracil—head and neck cancer	0.000807	0.00274	CcSEcCtD
Ziprasidone—Feeling abnormal—Vinblastine—head and neck cancer	0.000806	0.00274	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000799	0.00272	CcSEcCtD
Ziprasidone—Alopecia—Fluorouracil—head and neck cancer	0.000798	0.00271	CcSEcCtD
Ziprasidone—H1F0—lymph node—head and neck cancer	0.000798	0.00433	CbGeAlD
Ziprasidone—Dyspnoea—Hydroxyurea—head and neck cancer	0.000795	0.0027	CcSEcCtD
Ziprasidone—Angina pectoris—Docetaxel—head and neck cancer	0.000793	0.0027	CcSEcCtD
Ziprasidone—Somnolence—Hydroxyurea—head and neck cancer	0.000793	0.00269	CcSEcCtD
Ziprasidone—Erythema—Fluorouracil—head and neck cancer	0.000786	0.00267	CcSEcCtD
Ziprasidone—Dyspepsia—Hydroxyurea—head and neck cancer	0.000785	0.00267	CcSEcCtD
Ziprasidone—Decreased appetite—Hydroxyurea—head and neck cancer	0.000775	0.00263	CcSEcCtD
Ziprasidone—Abdominal pain—Vinblastine—head and neck cancer	0.000773	0.00263	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00077	0.00262	CcSEcCtD
Ziprasidone—Fatigue—Hydroxyurea—head and neck cancer	0.000769	0.00261	CcSEcCtD
Ziprasidone—Constipation—Hydroxyurea—head and neck cancer	0.000762	0.00259	CcSEcCtD
Ziprasidone—HRH1—trachea—head and neck cancer	0.000748	0.00406	CbGeAlD
Ziprasidone—HTR2A—connective tissue—head and neck cancer	0.000744	0.00404	CbGeAlD
Ziprasidone—Weight increased—Docetaxel—head and neck cancer	0.000741	0.00252	CcSEcCtD
Ziprasidone—Vision blurred—Fluorouracil—head and neck cancer	0.000741	0.00252	CcSEcCtD
Ziprasidone—CHRM3—head—head and neck cancer	0.000739	0.00401	CbGeAlD
Ziprasidone—Weight decreased—Docetaxel—head and neck cancer	0.000737	0.0025	CcSEcCtD
Ziprasidone—HTR1A—head—head and neck cancer	0.000736	0.004	CbGeAlD
Ziprasidone—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000735	0.0025	CcSEcCtD
Ziprasidone—ADRA2A—trachea—head and neck cancer	0.000735	0.00399	CbGeAlD
Ziprasidone—Pneumonia—Docetaxel—head and neck cancer	0.00073	0.00248	CcSEcCtD
Ziprasidone—Anaemia—Fluorouracil—head and neck cancer	0.000727	0.00247	CcSEcCtD
Ziprasidone—Infestation—Docetaxel—head and neck cancer	0.000726	0.00247	CcSEcCtD
Ziprasidone—Infestation NOS—Docetaxel—head and neck cancer	0.000726	0.00247	CcSEcCtD
Ziprasidone—Hypersensitivity—Vinblastine—head and neck cancer	0.00072	0.00245	CcSEcCtD
Ziprasidone—Renal failure—Docetaxel—head and neck cancer	0.000714	0.00243	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000712	0.00242	CcSEcCtD
Ziprasidone—Jaundice—Docetaxel—head and neck cancer	0.000708	0.00241	CcSEcCtD
Ziprasidone—HTR2A—epithelium—head and neck cancer	0.000706	0.00384	CbGeAlD
Ziprasidone—Conjunctivitis—Docetaxel—head and neck cancer	0.000706	0.0024	CcSEcCtD
Ziprasidone—Body temperature increased—Hydroxyurea—head and neck cancer	0.000705	0.0024	CcSEcCtD
Ziprasidone—Leukopenia—Fluorouracil—head and neck cancer	0.000704	0.00239	CcSEcCtD
Ziprasidone—HTR7—head—head and neck cancer	0.000703	0.00382	CbGeAlD
Ziprasidone—Asthenia—Vinblastine—head and neck cancer	0.000701	0.00238	CcSEcCtD
Ziprasidone—Epistaxis—Docetaxel—head and neck cancer	0.000685	0.00233	CcSEcCtD
Ziprasidone—ADRA1A—head—head and neck cancer	0.000678	0.00368	CbGeAlD
Ziprasidone—Myalgia—Fluorouracil—head and neck cancer	0.000669	0.00228	CcSEcCtD
Ziprasidone—Chest pain—Fluorouracil—head and neck cancer	0.000669	0.00228	CcSEcCtD
Ziprasidone—Diarrhoea—Vinblastine—head and neck cancer	0.000669	0.00227	CcSEcCtD
Ziprasidone—DRD2—head—head and neck cancer	0.000665	0.00361	CbGeAlD
Ziprasidone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000657	0.00223	CcSEcCtD
Ziprasidone—Haemoglobin—Docetaxel—head and neck cancer	0.000655	0.00223	CcSEcCtD
Ziprasidone—KCNH2—head—head and neck cancer	0.000655	0.00356	CbGeAlD
Ziprasidone—Rhinitis—Docetaxel—head and neck cancer	0.000654	0.00222	CcSEcCtD
Ziprasidone—Haemorrhage—Docetaxel—head and neck cancer	0.000652	0.00222	CcSEcCtD
Ziprasidone—Hepatitis—Docetaxel—head and neck cancer	0.000652	0.00222	CcSEcCtD
Ziprasidone—Hypoaesthesia—Docetaxel—head and neck cancer	0.000649	0.0022	CcSEcCtD
Ziprasidone—Confusional state—Fluorouracil—head and neck cancer	0.000647	0.0022	CcSEcCtD
Ziprasidone—Pharyngitis—Docetaxel—head and neck cancer	0.000647	0.0022	CcSEcCtD
Ziprasidone—Dizziness—Vinblastine—head and neck cancer	0.000646	0.0022	CcSEcCtD
Ziprasidone—ADRA2C—head—head and neck cancer	0.000646	0.00351	CbGeAlD
Ziprasidone—Urinary tract disorder—Docetaxel—head and neck cancer	0.000644	0.00219	CcSEcCtD
Ziprasidone—Oedema peripheral—Docetaxel—head and neck cancer	0.000642	0.00218	CcSEcCtD
Ziprasidone—Connective tissue disorder—Docetaxel—head and neck cancer	0.000641	0.00218	CcSEcCtD
Ziprasidone—Asthenia—Hydroxyurea—head and neck cancer	0.00064	0.00217	CcSEcCtD
Ziprasidone—Urethral disorder—Docetaxel—head and neck cancer	0.000639	0.00217	CcSEcCtD
Ziprasidone—Infection—Fluorouracil—head and neck cancer	0.000637	0.00217	CcSEcCtD
Ziprasidone—CYP1A2—thyroid gland—head and neck cancer	0.000632	0.00343	CbGeAlD
Ziprasidone—Nervous system disorder—Fluorouracil—head and neck cancer	0.000629	0.00214	CcSEcCtD
Ziprasidone—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000628	0.00214	CcSEcCtD
Ziprasidone—Visual impairment—Docetaxel—head and neck cancer	0.000628	0.00214	CcSEcCtD
Ziprasidone—Tachycardia—Fluorouracil—head and neck cancer	0.000626	0.00213	CcSEcCtD
Ziprasidone—HTR2A—trachea—head and neck cancer	0.000625	0.00339	CbGeAlD
Ziprasidone—Vomiting—Vinblastine—head and neck cancer	0.000622	0.00211	CcSEcCtD
Ziprasidone—Headache—Vinblastine—head and neck cancer	0.000612	0.00208	CcSEcCtD
Ziprasidone—Anorexia—Fluorouracil—head and neck cancer	0.000612	0.00208	CcSEcCtD
Ziprasidone—Diarrhoea—Hydroxyurea—head and neck cancer	0.00061	0.00207	CcSEcCtD
Ziprasidone—Eye disorder—Docetaxel—head and neck cancer	0.000609	0.00207	CcSEcCtD
Ziprasidone—Cardiac disorder—Docetaxel—head and neck cancer	0.000605	0.00206	CcSEcCtD
Ziprasidone—Hypotension—Fluorouracil—head and neck cancer	0.0006	0.00204	CcSEcCtD
Ziprasidone—Angiopathy—Docetaxel—head and neck cancer	0.000591	0.00201	CcSEcCtD
Ziprasidone—Dizziness—Hydroxyurea—head and neck cancer	0.00059	0.002	CcSEcCtD
Ziprasidone—Immune system disorder—Docetaxel—head and neck cancer	0.000589	0.002	CcSEcCtD
Ziprasidone—Mediastinal disorder—Docetaxel—head and neck cancer	0.000587	0.002	CcSEcCtD
Ziprasidone—Chills—Docetaxel—head and neck cancer	0.000585	0.00199	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000585	0.00199	CcSEcCtD
Ziprasidone—Arrhythmia—Docetaxel—head and neck cancer	0.000582	0.00198	CcSEcCtD
Ziprasidone—ADRA2A—thyroid gland—head and neck cancer	0.000581	0.00316	CbGeAlD
Ziprasidone—Nausea—Vinblastine—head and neck cancer	0.000581	0.00197	CcSEcCtD
Ziprasidone—Insomnia—Fluorouracil—head and neck cancer	0.00058	0.00197	CcSEcCtD
Ziprasidone—Paraesthesia—Fluorouracil—head and neck cancer	0.000576	0.00196	CcSEcCtD
Ziprasidone—Alopecia—Docetaxel—head and neck cancer	0.000576	0.00196	CcSEcCtD
Ziprasidone—Dyspnoea—Fluorouracil—head and neck cancer	0.000572	0.00194	CcSEcCtD
Ziprasidone—Mental disorder—Docetaxel—head and neck cancer	0.000571	0.00194	CcSEcCtD
Ziprasidone—Somnolence—Fluorouracil—head and neck cancer	0.00057	0.00194	CcSEcCtD
Ziprasidone—Erythema—Docetaxel—head and neck cancer	0.000567	0.00193	CcSEcCtD
Ziprasidone—Malnutrition—Docetaxel—head and neck cancer	0.000567	0.00193	CcSEcCtD
Ziprasidone—Vomiting—Hydroxyurea—head and neck cancer	0.000567	0.00193	CcSEcCtD
Ziprasidone—Dyspepsia—Fluorouracil—head and neck cancer	0.000565	0.00192	CcSEcCtD
Ziprasidone—Rash—Hydroxyurea—head and neck cancer	0.000562	0.00191	CcSEcCtD
Ziprasidone—Dermatitis—Hydroxyurea—head and neck cancer	0.000562	0.00191	CcSEcCtD
Ziprasidone—Headache—Hydroxyurea—head and neck cancer	0.000558	0.0019	CcSEcCtD
Ziprasidone—Decreased appetite—Fluorouracil—head and neck cancer	0.000558	0.0019	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000554	0.00188	CcSEcCtD
Ziprasidone—Back pain—Docetaxel—head and neck cancer	0.000549	0.00187	CcSEcCtD
Ziprasidone—Muscle spasms—Docetaxel—head and neck cancer	0.000546	0.00185	CcSEcCtD
Ziprasidone—Nausea—Hydroxyurea—head and neck cancer	0.00053	0.0018	CcSEcCtD
Ziprasidone—Feeling abnormal—Fluorouracil—head and neck cancer	0.000529	0.0018	CcSEcCtD
Ziprasidone—HRH1—head—head and neck cancer	0.000525	0.00285	CbGeAlD
Ziprasidone—Anaemia—Docetaxel—head and neck cancer	0.000524	0.00178	CcSEcCtD
Ziprasidone—ADRA2A—head—head and neck cancer	0.000516	0.0028	CbGeAlD
Ziprasidone—Urticaria—Fluorouracil—head and neck cancer	0.00051	0.00173	CcSEcCtD
Ziprasidone—Syncope—Docetaxel—head and neck cancer	0.000509	0.00173	CcSEcCtD
Ziprasidone—Leukopenia—Docetaxel—head and neck cancer	0.000508	0.00173	CcSEcCtD
Ziprasidone—Body temperature increased—Fluorouracil—head and neck cancer	0.000507	0.00172	CcSEcCtD
Ziprasidone—Palpitations—Docetaxel—head and neck cancer	0.000501	0.0017	CcSEcCtD
Ziprasidone—Loss of consciousness—Docetaxel—head and neck cancer	0.000499	0.0017	CcSEcCtD
Ziprasidone—Cough—Docetaxel—head and neck cancer	0.000495	0.00168	CcSEcCtD
Ziprasidone—Hypertension—Docetaxel—head and neck cancer	0.00049	0.00167	CcSEcCtD
Ziprasidone—Chest pain—Docetaxel—head and neck cancer	0.000483	0.00164	CcSEcCtD
Ziprasidone—Arthralgia—Docetaxel—head and neck cancer	0.000483	0.00164	CcSEcCtD
Ziprasidone—Myalgia—Docetaxel—head and neck cancer	0.000483	0.00164	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00048	0.00163	CcSEcCtD
Ziprasidone—Hypersensitivity—Fluorouracil—head and neck cancer	0.000473	0.00161	CcSEcCtD
Ziprasidone—Dry mouth—Docetaxel—head and neck cancer	0.000472	0.00161	CcSEcCtD
Ziprasidone—Confusional state—Docetaxel—head and neck cancer	0.000467	0.00159	CcSEcCtD
Ziprasidone—Infection—Docetaxel—head and neck cancer	0.00046	0.00156	CcSEcCtD
Ziprasidone—KCNH2—lymph node—head and neck cancer	0.000459	0.00249	CbGeAlD
Ziprasidone—Shock—Docetaxel—head and neck cancer	0.000456	0.00155	CcSEcCtD
Ziprasidone—Nervous system disorder—Docetaxel—head and neck cancer	0.000454	0.00154	CcSEcCtD
Ziprasidone—Thrombocytopenia—Docetaxel—head and neck cancer	0.000453	0.00154	CcSEcCtD
Ziprasidone—ADRA2C—lymph node—head and neck cancer	0.000452	0.00246	CbGeAlD
Ziprasidone—Tachycardia—Docetaxel—head and neck cancer	0.000452	0.00154	CcSEcCtD
Ziprasidone—Skin disorder—Docetaxel—head and neck cancer	0.00045	0.00153	CcSEcCtD
Ziprasidone—Anorexia—Docetaxel—head and neck cancer	0.000441	0.0015	CcSEcCtD
Ziprasidone—Diarrhoea—Fluorouracil—head and neck cancer	0.000439	0.00149	CcSEcCtD
Ziprasidone—HTR2A—head—head and neck cancer	0.000438	0.00238	CbGeAlD
Ziprasidone—Hypotension—Docetaxel—head and neck cancer	0.000433	0.00147	CcSEcCtD
Ziprasidone—Dizziness—Fluorouracil—head and neck cancer	0.000424	0.00144	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000422	0.00143	CcSEcCtD
Ziprasidone—Insomnia—Docetaxel—head and neck cancer	0.000419	0.00142	CcSEcCtD
Ziprasidone—Paraesthesia—Docetaxel—head and neck cancer	0.000416	0.00141	CcSEcCtD
Ziprasidone—Dyspnoea—Docetaxel—head and neck cancer	0.000413	0.0014	CcSEcCtD
Ziprasidone—Somnolence—Docetaxel—head and neck cancer	0.000412	0.0014	CcSEcCtD
Ziprasidone—Vomiting—Fluorouracil—head and neck cancer	0.000408	0.00139	CcSEcCtD
Ziprasidone—Dyspepsia—Docetaxel—head and neck cancer	0.000408	0.00139	CcSEcCtD
Ziprasidone—Rash—Fluorouracil—head and neck cancer	0.000405	0.00138	CcSEcCtD
Ziprasidone—Dermatitis—Fluorouracil—head and neck cancer	0.000404	0.00137	CcSEcCtD
Ziprasidone—Decreased appetite—Docetaxel—head and neck cancer	0.000403	0.00137	CcSEcCtD
Ziprasidone—Headache—Fluorouracil—head and neck cancer	0.000402	0.00137	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.0004	0.00136	CcSEcCtD
Ziprasidone—CYP2D6—head—head and neck cancer	0.000399	0.00217	CbGeAlD
Ziprasidone—Fatigue—Docetaxel—head and neck cancer	0.000399	0.00136	CcSEcCtD
Ziprasidone—Constipation—Docetaxel—head and neck cancer	0.000396	0.00135	CcSEcCtD
Ziprasidone—Feeling abnormal—Docetaxel—head and neck cancer	0.000382	0.0013	CcSEcCtD
Ziprasidone—Nausea—Fluorouracil—head and neck cancer	0.000381	0.0013	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000379	0.00129	CcSEcCtD
Ziprasidone—HRH1—lymph node—head and neck cancer	0.000368	0.002	CbGeAlD
Ziprasidone—Body temperature increased—Docetaxel—head and neck cancer	0.000366	0.00124	CcSEcCtD
Ziprasidone—Abdominal pain—Docetaxel—head and neck cancer	0.000366	0.00124	CcSEcCtD
Ziprasidone—ADRA2A—lymph node—head and neck cancer	0.000361	0.00196	CbGeAlD
Ziprasidone—Hypersensitivity—Docetaxel—head and neck cancer	0.000341	0.00116	CcSEcCtD
Ziprasidone—Asthenia—Docetaxel—head and neck cancer	0.000332	0.00113	CcSEcCtD
Ziprasidone—Diarrhoea—Docetaxel—head and neck cancer	0.000317	0.00108	CcSEcCtD
Ziprasidone—Dizziness—Docetaxel—head and neck cancer	0.000306	0.00104	CcSEcCtD
Ziprasidone—Vomiting—Docetaxel—head and neck cancer	0.000294	0.001	CcSEcCtD
Ziprasidone—Rash—Docetaxel—head and neck cancer	0.000292	0.000993	CcSEcCtD
Ziprasidone—Dermatitis—Docetaxel—head and neck cancer	0.000292	0.000992	CcSEcCtD
Ziprasidone—Headache—Docetaxel—head and neck cancer	0.00029	0.000986	CcSEcCtD
Ziprasidone—Nausea—Docetaxel—head and neck cancer	0.000275	0.000935	CcSEcCtD
Ziprasidone—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.5e-05	9.86e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PTEN—head and neck cancer	1.5e-05	9.86e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.49e-05	9.81e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MAPK3—head and neck cancer	1.49e-05	9.8e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MAPK1—head and neck cancer	1.48e-05	9.78e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EGFR—head and neck cancer	1.48e-05	9.78e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.48e-05	9.74e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	1.48e-05	9.73e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MAPK3—head and neck cancer	1.47e-05	9.66e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	1.46e-05	9.62e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.45e-05	9.57e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—HRAS—head and neck cancer	1.45e-05	9.56e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	1.45e-05	9.54e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.43e-05	9.41e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—PIK3CA—head and neck cancer	1.42e-05	9.39e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—HRAS—head and neck cancer	1.42e-05	9.39e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	1.42e-05	9.39e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—PIK3CA—head and neck cancer	1.42e-05	9.38e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—HRAS—head and neck cancer	1.42e-05	9.36e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—HRAS—head and neck cancer	1.41e-05	9.33e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—PIK3CA—head and neck cancer	1.41e-05	9.32e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MAPK1—head and neck cancer	1.41e-05	9.32e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—head and neck cancer	1.41e-05	9.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	1.41e-05	9.31e-05	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	1.41e-05	9.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTEN—head and neck cancer	1.41e-05	9.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.4e-05	9.25e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—HRAS—head and neck cancer	1.4e-05	9.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	1.4e-05	9.22e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	1.4e-05	9.21e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL2—head and neck cancer	1.4e-05	9.2e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MAPK1—head and neck cancer	1.39e-05	9.2e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—head and neck cancer	1.39e-05	9.19e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	1.39e-05	9.16e-05	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.39e-05	9.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	1.39e-05	9.13e-05	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	1.38e-05	9.13e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	1.38e-05	9.13e-05	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—AKT1—head and neck cancer	1.38e-05	9.1e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—head and neck cancer	1.38e-05	9.09e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—head and neck cancer	1.38e-05	9.08e-05	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—AKT1—head and neck cancer	1.38e-05	9.07e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.37e-05	9.05e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL2—head and neck cancer	1.37e-05	9.03e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—head and neck cancer	1.37e-05	9.02e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL2—head and neck cancer	1.37e-05	9e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—PIK3CA—head and neck cancer	1.36e-05	8.98e-05	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—AKT1—head and neck cancer	1.36e-05	8.98e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL2—head and neck cancer	1.36e-05	8.97e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCND1—head and neck cancer	1.36e-05	8.97e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	1.36e-05	8.96e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	1.35e-05	8.9e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL2—head and neck cancer	1.35e-05	8.89e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—PIK3CA—head and neck cancer	1.34e-05	8.86e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL2—head and neck cancer	1.34e-05	8.86e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.34e-05	8.86e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—head and neck cancer	1.34e-05	8.83e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.34e-05	8.82e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—STAT3—head and neck cancer	1.34e-05	8.82e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCND1—head and neck cancer	1.34e-05	8.8e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCND1—head and neck cancer	1.33e-05	8.78e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.33e-05	8.77e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCND1—head and neck cancer	1.33e-05	8.75e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	1.32e-05	8.73e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—HRAS—head and neck cancer	1.32e-05	8.69e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—head and neck cancer	1.32e-05	8.69e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—HRAS—head and neck cancer	1.32e-05	8.68e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCND1—head and neck cancer	1.31e-05	8.66e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PTEN—head and neck cancer	1.31e-05	8.66e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	1.31e-05	8.64e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—HRAS—head and neck cancer	1.31e-05	8.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	1.31e-05	8.62e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—head and neck cancer	1.3e-05	8.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	1.3e-05	8.56e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	1.29e-05	8.53e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.29e-05	8.52e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTEN—head and neck cancer	1.29e-05	8.5e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTEN—head and neck cancer	1.29e-05	8.49e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PIK3CA—head and neck cancer	1.29e-05	8.49e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	1.29e-05	8.48e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTEN—head and neck cancer	1.28e-05	8.47e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HRAS—head and neck cancer	1.28e-05	8.45e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AKT1—head and neck cancer	1.28e-05	8.44e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—head and neck cancer	1.28e-05	8.44e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	1.28e-05	8.42e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.27e-05	8.38e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—head and neck cancer	1.27e-05	8.36e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	1.26e-05	8.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	1.26e-05	8.32e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—head and neck cancer	1.26e-05	8.31e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	1.26e-05	8.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	1.26e-05	8.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	1.26e-05	8.3e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—head and neck cancer	1.26e-05	8.29e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PIK3CA—head and neck cancer	1.26e-05	8.29e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—head and neck cancer	1.25e-05	8.26e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—head and neck cancer	1.25e-05	8.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—head and neck cancer	1.25e-05	8.23e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—head and neck cancer	1.25e-05	8.21e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—head and neck cancer	1.24e-05	8.2e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—head and neck cancer	1.24e-05	8.16e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	1.24e-05	8.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	1.23e-05	8.14e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—TYMS—head and neck cancer	1.23e-05	8.12e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.23e-05	8.1e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PIK3CA—head and neck cancer	1.23e-05	8.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PIK3CA—head and neck cancer	1.22e-05	8.05e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.22e-05	8.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	1.22e-05	8.03e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	1.22e-05	8.02e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	1.22e-05	8.01e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—head and neck cancer	1.22e-05	8.01e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PIK3CA—head and neck cancer	1.21e-05	7.98e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	1.21e-05	7.97e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—head and neck cancer	1.21e-05	7.97e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—head and neck cancer	1.19e-05	7.85e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—head and neck cancer	1.19e-05	7.82e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—head and neck cancer	1.19e-05	7.82e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	1.18e-05	7.76e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	1.18e-05	7.75e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	1.18e-05	7.75e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—head and neck cancer	1.17e-05	7.74e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—head and neck cancer	1.17e-05	7.72e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	1.17e-05	7.69e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GPX1—head and neck cancer	1.17e-05	7.69e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—head and neck cancer	1.16e-05	7.68e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—head and neck cancer	1.16e-05	7.67e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—head and neck cancer	1.16e-05	7.67e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—head and neck cancer	1.16e-05	7.65e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	1.16e-05	7.63e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	1.16e-05	7.63e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—head and neck cancer	1.16e-05	7.63e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—head and neck cancer	1.16e-05	7.62e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—head and neck cancer	1.16e-05	7.62e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.15e-05	7.61e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—head and neck cancer	1.15e-05	7.6e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—head and neck cancer	1.15e-05	7.58e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	1.15e-05	7.56e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—head and neck cancer	1.15e-05	7.55e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—head and neck cancer	1.15e-05	7.55e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	1.14e-05	7.53e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—head and neck cancer	1.13e-05	7.48e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—head and neck cancer	1.13e-05	7.48e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—head and neck cancer	1.13e-05	7.46e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	1.13e-05	7.46e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK3—head and neck cancer	1.12e-05	7.4e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—head and neck cancer	1.12e-05	7.38e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—head and neck cancer	1.11e-05	7.34e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	1.1e-05	7.28e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK3—head and neck cancer	1.1e-05	7.26e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—head and neck cancer	1.1e-05	7.24e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK3—head and neck cancer	1.1e-05	7.24e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK3—head and neck cancer	1.09e-05	7.21e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	1.09e-05	7.2e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK3—head and neck cancer	1.08e-05	7.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	1.08e-05	7.13e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PIK3CA—head and neck cancer	1.08e-05	7.12e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK1—head and neck cancer	1.07e-05	7.04e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—head and neck cancer	1.07e-05	7.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	1.06e-05	7e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—head and neck cancer	1.06e-05	6.97e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	1.05e-05	6.95e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—head and neck cancer	1.05e-05	6.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	1.05e-05	6.93e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	1.05e-05	6.92e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.05e-05	6.92e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—head and neck cancer	1.05e-05	6.92e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	1.05e-05	6.92e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK1—head and neck cancer	1.05e-05	6.91e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—head and neck cancer	1.05e-05	6.91e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK1—head and neck cancer	1.04e-05	6.89e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—head and neck cancer	1.04e-05	6.89e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK1—head and neck cancer	1.04e-05	6.86e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—head and neck cancer	1.04e-05	6.86e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK1—head and neck cancer	1.03e-05	6.8e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—head and neck cancer	1.03e-05	6.8e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	1.03e-05	6.78e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	1.03e-05	6.78e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—head and neck cancer	1.03e-05	6.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	1.02e-05	6.73e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—head and neck cancer	1.02e-05	6.73e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—head and neck cancer	1.02e-05	6.69e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	1.01e-05	6.67e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	1e-05	6.62e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	1e-05	6.62e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—head and neck cancer	1e-05	6.61e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—head and neck cancer	9.97e-06	6.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PIK3CA—head and neck cancer	9.91e-06	6.54e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—head and neck cancer	9.89e-06	6.52e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—head and neck cancer	9.87e-06	6.51e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—head and neck cancer	9.76e-06	6.43e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—head and neck cancer	9.72e-06	6.41e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—head and neck cancer	9.71e-06	6.4e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	9.55e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	9.55e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	9.44e-06	6.23e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	9.29e-06	6.13e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	9.26e-06	6.11e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—head and neck cancer	9.16e-06	6.04e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	9.11e-06	6.01e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	9.09e-06	6e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PIK3CA—head and neck cancer	9.08e-06	5.99e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PIK3CA—head and neck cancer	9.06e-06	5.98e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PIK3CA—head and neck cancer	9.03e-06	5.96e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—head and neck cancer	8.96e-06	5.91e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PIK3CA—head and neck cancer	8.95e-06	5.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	8.93e-06	5.89e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	8.92e-06	5.88e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—head and neck cancer	8.9e-06	5.87e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—head and neck cancer	8.83e-06	5.82e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—head and neck cancer	8.81e-06	5.81e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—head and neck cancer	8.8e-06	5.8e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—head and neck cancer	8.77e-06	5.78e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—head and neck cancer	8.74e-06	5.76e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—head and neck cancer	8.65e-06	5.71e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—head and neck cancer	8.63e-06	5.69e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—head and neck cancer	8.62e-06	5.68e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—head and neck cancer	8.57e-06	5.65e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—head and neck cancer	8.57e-06	5.65e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—head and neck cancer	8.43e-06	5.56e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—head and neck cancer	8.41e-06	5.55e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—head and neck cancer	8.39e-06	5.53e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—head and neck cancer	8.36e-06	5.51e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	8.34e-06	5.5e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	8.29e-06	5.47e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—head and neck cancer	8.28e-06	5.46e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	8.25e-06	5.44e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	8.21e-06	5.41e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—head and neck cancer	8.1e-06	5.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—head and neck cancer	8.02e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—head and neck cancer	7.76e-06	5.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	7.67e-06	5.06e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—head and neck cancer	7.56e-06	4.99e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—head and neck cancer	7.44e-06	4.91e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—head and neck cancer	7.43e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—head and neck cancer	7.42e-06	4.89e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—head and neck cancer	7.4e-06	4.88e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—head and neck cancer	7.38e-06	4.87e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—head and neck cancer	7.31e-06	4.82e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	7.29e-06	4.81e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—head and neck cancer	6.87e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	6.77e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CA—head and neck cancer	6.46e-06	4.26e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—head and neck cancer	5.99e-06	3.95e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CA—head and neck cancer	5.47e-06	3.61e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—head and neck cancer	5.28e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—head and neck cancer	4.47e-06	2.95e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.22e-06	2.78e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—head and neck cancer	3.45e-06	2.28e-05	CbGpPWpGaD
